Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15415674 | 1.00 | CYP1A2 (0.40) | CYP1A2CXCR4CHKAHRH4CNR2 | |
| SCHEMBL1526838 | 0.98 | CHKA (0.39) | CYP1A2CXCR4CHKAHRH4CNR2 | |
| SCHEMBL15415235 | 0.94 | CHKA (0.34) | CYP1A2CXCR4CHKAHRH4CNR2 | |
| SCHEMBL1521529 | 0.81 | ALDH1A1 (0.33) | CNR2ALDH1A1MAPTRAB9AKDM4E | |
| SCHEMBL1110243 | 0.81 | PIK3CA (0.44) | CYP1A2HPGDALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL934301 | 0.81 | HRH4 (0.49) | CYP1A2HRH4ALDH1A1KDM4ETSHR | |
| SCHEMBL1110327 | 0.81 | PLD1 (0.49) | CYP1A2HRH4ALDH1A1MAPK1KDM4E | |
| SCHEMBL12615573 | 0.77 | RXFP1 (0.46) | HPGDALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL12615235 | 0.77 | MAP4K4 (0.44) | HRH4 | |
| SCHEMBL12614647 | 0.77 | SMPD3 (0.43) | ALDH1A1NPC1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | claimed |
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | claimed |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | AMGEM INC. (US) | 2014-07-03 | — | — | US | claimed |
| EP-2688886-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-01-29 | — | — | EP | claimed |
| WO-2012129338-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-09-27 | — | — | WO | claimed |
| EP-0465369-B1 | N-substituted derivatives of alpha-mercapto alkylamines, process for their preparation and intermediates obtained, their use as medicaments and compositions containing them | ROUSSEL UCLAF (FR) | 1994-04-13 | — | — | EP | claimed |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2024-02-27 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | disclosed |
| EP-3436456-B1 | FUSED HEXACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3436460-B1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-08-18 | — | — | EP | disclosed |
| CN-107690434-B | Fused tricyclic imidazopyrazine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-07-30 | — | — | CN | disclosed |
| WO-2014009296-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013186229-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB PHARMA S.A. (BE) | 2013-12-19 | — | — | WO | disclosed |
| US-8575336-B2 | Indazoles | PFIZER LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| WO-2013014567-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| US-20130029968-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2012129338-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029968-A1 | INDAZOLES | CYP11B2, CYP11B1, IL33 | CYP1A2 9/4885CXCR4 681/4885CHKA 994/4885 |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | PIM1, PIM3, PIM2 | CYP1A2 280/4885CXCR4 2621/4885CHKA 1813/4885 |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | TNF, NFKBIA, TNFRSF1A | CYP1A2 664/4885CXCR4 1595/4885CHKA 1244/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CYP1A2 1905/4885CXCR4 2666/4885CHKA 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.